Childhood spinal muscular atrophy

Alías, 2009, Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene, Hum Genet, 125, 29, 10.1007/s00439-008-0598-1 Angelozzi, 2008, Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells, J Med Genet, 45, 29, 10.1136/jmg.2007.051177 Arts, 2011, Muscle ultrasonography to predict survival in amyotrophic lateral sclerosis, J Neurol Neurosurg Psychiatry, 82, 552, 10.1136/jnnp.2009.200519 Bach, 1994, Update and perspectives on noninvasive respiratory muscle aids. Part 1: the inspiratory aids, Chest, 105, 1230, 10.1378/chest.105.4.1230 Baranello, 2021, Risdiplam in type 1 spinal muscular atrophy, N Engl J Med, 384, 915, 10.1056/NEJMoa2009965 Barth, 1993, Pontocerebellar hypoplasias: an overview of a group of inherited neurodegenerative disorders with fetal onset, Brain Dev, 15, 411, 10.1016/0387-7604(93)90080-R Baumbach, 1994, X-linked lethal infantile spinal muscular atrophy: from clinical description to molecular mapping, Am J Hum Genet, 55, A211 Bernal, 2010, The c.859G>C variant in the SMN2 gene is associated with types II and III SMA and originates from a common ancestor, J Med Genet, 47, 640, 10.1136/jmg.2010.079004 Bertini, 1989, Distal infantile spinal muscular atrophy associated with paralysis of the diaphragm: a variant of infantile spinal muscular atrophy, Am J Med Genet, 33, 328, 10.1002/ajmg.1320330309 Bertini, 2017, Efficacy and safety of nusinersen in infants with presymptomatic spinal muscular atrophy (SMA): interim results from the NURTURE study, Eur J Paediatr Neurol, 21, 10.1016/j.ejpn.2017.04.1218 Bingham, 1997, Arthrogryposis due to infantile neuronal degeneration associated with deletion of the SMNT gene, Neurology, 49, 848, 10.1212/WNL.49.3.848 Blazej, 1998, Hereditary canine spinal muscular atrophy is phenotypically similar but molecularly distinct from human spinal muscular atrophy, J Hered, 89, 531, 10.1093/jhered/89.6.531 Bromberg, 1993, Motor unit estimation: reproducibility of the spike-triggered averaging technique in normal and ALS subjects, Muscle Nerve, 16, 466, 10.1002/mus.880160506 Bromberg, 2002, Motor unit number estimation in infants and children with spinal muscular atrophy, Muscle Nerve, 25, 445, 10.1002/mus.10050 Bürglen, 1995, SMN gene deletion in variant of infantile spinal muscular atrophy, Lancet, 346, 316, 10.1016/S0140-6736(95)92206-7 Byers, 1961, Infantile muscular atrophy, Arch Neurol, 5, 140, 10.1001/archneur.1961.00450140022003 Calucho, 2018, Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases, Neuromuscul Disord, 28, 208, 10.1016/j.nmd.2018.01.003 Catapano, 2016, Altered levels of microRNA-9, -206, and -132 in spinal muscular atrophy and their response to antisense oligonucleotide therapy, Mol Ther Nucleic Acids, 5, 10.1038/mtna.2016.47 Chou, 1990, Infantile olivopontocerebellar atrophy with spinal muscular atrophy (infantile OPCA + SMA), Clin Neuropathol, 9, 21 Dangouloff, 2021, Newborn screening programs for spinal muscular atrophy worldwide: where we stand and where to go, Neuromuscul Disord, 31, 574, 10.1016/j.nmd.2021.03.007 Darras, 2018, Precious SMA natural history data: a benchmark to measure future treatment successes, Neurology, 91, 337, 10.1212/WNL.0000000000006026 Darras, 2019, Neurofilament as a potential biomarker for spinal muscular atrophy, Ann Clin Transl Neurol, 6, 932, 10.1002/acn3.779 Darras, 2021, Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls, N Engl J Med, 385, 427, 10.1056/NEJMoa2102047 Day, 2021, Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial, Lancet Neurol, 20, 284, 10.1016/S1474-4422(21)00001-6 De Vivo, 2019, Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study, Neuromuscul Disord, 29, 842, 10.1016/j.nmd.2019.09.007 Detering, 2022, The phospho-landscape of the survival of motoneuron protein (SMN) protein: relevance for spinal muscular atrophy (SMA), Cell Mol Life Sci, 79, 497, 10.1007/s00018-022-04522-9 Devriendt, 1996, Clinical and molecular genetic features of congenital spinal muscular atrophy, Ann Neurol, 40, 731, 10.1002/ana.410400509 Dubowitz, 1964, Infantile muscular atrophy: a prospective study with particular reference to a slowly progressive variety, Brain, 87, 707, 10.1093/brain/87.4.707 Dubowitz, 1995, Chaos in the classification of SMA: a possible resolution, Neuromuscul Disord, 5, 3, 10.1016/0960-8966(94)00075-K Dubowitz, 1999, Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype, Eur J Paediatr Neurol, 3, 49, 10.1016/S1090-3798(99)80012-9 Durmus, 2017, Muscle magnetic resonance imaging in spinal muscular atrophy type 3: selective and progressive involvement, Muscle Nerve, 55, 651, 10.1002/mus.25385 D'ydewalle, 2017, The antisense transcript SMN-AS1 regulates SMN expression and is a novel therapeutic target for spinal muscular atrophy, Neuron, 93, 66, 10.1016/j.neuron.2016.11.033 Eng, 1984, Spinal muscular atrophy: experience in diagnosis and rehabilitation management of 60 patients, Arch Phys Med Rehabil, 65, 549 Farrar, 2011, Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophy, Brain, 134, 3185, 10.1093/brain/awr229 Ferri, 2004, Progressive and selective degeneration of motoneurons in a mouse model of SMA, Neuroreport, 15, 275, 10.1097/00001756-200402090-00013 Finkel, 2014, Observational study of spinal muscular atrophy type I and implications for clinical trials, Neurology, 83, 810, 10.1212/WNL.0000000000000741 Finkel, 2017, Nusinersen versus sham control in infantile-onset spinal muscular atrophy, N Engl J Med, 377, 1723, 10.1056/NEJMoa1702752 Finkel, 2018, Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics, Neuromuscul Disord, 28, 197, 10.1016/j.nmd.2017.11.004 Finkel, 2021, Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study, Lancet Child Adolesc Health, 5, 491, 10.1016/S2352-4642(21)00100-0 Foust, 2009, Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes, Nat Biotechnol, 27, 59, 10.1038/nbt.1515 García-Cabezas, 2004, Neonatal spinal muscular atrophy with multiple contractures, bone fractures, respiratory insufficiency and 5q13 deletion, Acta Neuropathol, 107, 475, 10.1007/s00401-004-0825-3 Gawel, 2015, Motor unit loss estimation by the multipoint incremental MUNE method in children with spinal muscular atrophy—a preliminary study, Neuromuscul Disord, 25, 216, 10.1016/j.nmd.2014.11.012 Gilliam, 1990, Genetic homogeneity between acute and chronic forms of spinal muscular atrophy, Nature, 345, 823, 10.1038/345823a0 Glanzman, 2010, The Children's Hospital of Philadelphia infant test of neuromuscular disorders (CHOP INTEND): test development and reliability, Neuromuscul Disord, 20, 155, 10.1016/j.nmd.2009.11.014 Glascock, 2018, Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening, J Neuromuscul Dis, 5, 145, 10.3233/JND-180304 Glascock, 2020, Revised recommendations for the treatment of infants diagnosed with spinal muscular atrophy via newborn screening who have 4 copies of SMN2, J Neuromuscul Dis, 7, 97, 10.3233/JND-190468 Graham, 2010, Molecular and neuroimaging findings in pontocerebellar hypoplasia type 2 (PCH2): is prenatal diagnosis possible?, Am J Med Genet A, 152a, 2268, 10.1002/ajmg.a.33579 Greenberg, 1988, X-linked infantile spinal muscular atrophy, Am J Dis Child, 142, 217 Groger, 1990, Guido Werdnig, 383 Grohmann, 1999, Diaphragmatic spinal muscular atrophy with respiratory distress is heterogeneous, and one form is linked to chromosome 11q13-q21, Am J Hum Genet, 65, 1459, 10.1086/302636 Grohmann, 2003, Infantile spinal muscular atrophy with respiratory distress type 1 (SMARD1), Ann Neurol, 54, 719, 10.1002/ana.10755 Hahnen, 1996, Hybrid survival motor neuron genes in patients with autosomal recessive spinal muscular atrophy: new insights into molecular mechanisms responsible for the disease, Am J Hum Genet, 59, 1057 Henderson, 2017, Assessment of motor units in neuromuscular disease, Neurotherapeutics, 14, 69, 10.1007/s13311-016-0473-z Hirtz, 2005, Challenges and opportunities in clinical trials for spinal muscular atrophy, Neurology, 65, 1352, 10.1212/01.wnl.0000183282.10946.c7 Hoffmann, 1892, Ueberfamiliare progressive spinale muskelatrophie, Arch Psych (Berlin), 24, 644 Iijima, 1991, Maximal and minimal motor nerve conduction velocities in patients with motor neuron diseases: correlation with age of onset and duration of illness, Muscle Nerve, 14, 1110, 10.1002/mus.880141112 Jablonka, 2000, The role of SMN in spinal muscular atrophy, J Neurol, 247, I37, 10.1007/s004150050555 Jedrzejowska, 2008, Unaffected patients with a homozygous absence of the SMN1 gene, Eur J Hum Genet, 16, 930, 10.1038/ejhg.2008.41 Jullien De Pommerol, 2018, SMA therapies II and biomarkers: neurofilament light chain as a potential biomarker in spinal muscular atrophy, Neuromuscul Disord, 28, S111, 10.1016/j.nmd.2018.06.311 Kariyawasam, 2019, Biomarkers and the development of a personalized medicine approach in spinal muscular atrophy, Front Neurol, 10, 898, 10.3389/fneur.2019.00898 Kaupmann, 1992, Wobbler, a mutation affecting motoneuron survival and gonadal functions in the mouse, maps to proximal chromosome 11, Genomics, 13, 39, 10.1016/0888-7543(92)90199-3 Kennedy, 1968, Progressive proximal spinal and bulbar muscular atrophy of late onset: a sex-linked recessive trait, Neurology, 18, 671, 10.1212/WNL.18.7.671 Kennerson, 2009, X-linked distal hereditary motor neuropathy maps to the DSMAX locus on chromosome Xq13.1-q21, Neurology, 72, 246, 10.1212/01.wnl.0000339483.86094.a5 Klotz, 2021, Advances in the therapy of spinal muscular atrophy, J Pediatr, 236, 10.1016/j.jpeds.2021.06.033 Kolb, 2017, Natural history of infantile-onset spinal muscular atrophy, Ann Neurol, 82, 883, 10.1002/ana.25101 La Spada, 1991, Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy, Nature, 352, 77, 10.1038/352077a0 La Spada, 1992, Meiotic stability and genotype-phenotype correlation of the trinucleotide repeat in X-linked spinal and bulbar muscular atrophy, Nat Genet, 2, 301, 10.1038/ng1292-301 Lee, 2021, Time is muscle: a recommendation for early treatment for preterm infants with spinal muscular atrophy, Muscle Nerve, 64, 153, 10.1002/mus.27261 Lefebvre, 1995, Identification and characterization of a spinal muscular atrophy-determining gene, Cell, 80, 155, 10.1016/0092-8674(95)90460-3 Macleod, 1999, Prenatal onset spinal muscular atrophy, Eur J Paediatr Neurol, 3, 65, 10.1016/S1090-3798(99)80015-4 Mailman, 2002, Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2, Genet Med, 4, 20, 10.1097/00125817-200201000-00004 Manzur, 2003, Muscular dystrophy campaign sponsored workshop: recommendation for respiratory care of children with spinal muscular atrophy type II and III. 13th February 2002, London, UK Neuromuscul Disord, 13, 184, 10.1016/S0960-8966(02)00212-2 Masson, 2022, Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial, Lancet Neurol, 21, 1110, 10.1016/S1474-4422(22)00339-8 Matthijs, 1996, Unusual molecular findings in autosomal recessive spinal muscular atrophy, J Med Genet, 33, 469, 10.1136/jmg.33.6.469 Mcwhorter, 2003, Knockdown of the survival motor neuron (SMN) protein in zebrafish causes defects in motor axon outgrowth and pathfinding, J Cell Biol, 162, 919, 10.1083/jcb.200303168 Melki, 1990, Mapping of acute (type I) spinal muscular atrophy to chromosome 5q12-q14, Lancet, 336, 271, 10.1016/0140-6736(90)91803-I Melki, 1994, De novo and inherited deletions of the 5q13 region in spinal muscular atrophies, Science, 264, 1474, 10.1126/science.7910982 Mellins, 1974, Respiratory distress as the initial manifestation of Werdnig-Hoffmann disease, Pediatrics, 53, 33, 10.1542/peds.53.1.33 Mendell, 2017, Single-dose gene-replacement therapy for spinal muscular atrophy, N Engl J Med, 377, 1713, 10.1056/NEJMoa1706198 Mendell, 2021, Five-year extension results of the phase 1 START trial of Onasemnogene Abeparvovec in spinal muscular atrophy, JAMA Neurol, 78, 834, 10.1001/jamaneurol.2021.1272 Mercuri, 2018, Nusinersen versus sham control in later-onset spinal muscular atrophy, N Engl J Med, 378, 625, 10.1056/NEJMoa1710504 Mercuri, 2018, Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care, Neuromuscul Disord, 28, 103, 10.1016/j.nmd.2017.11.005 Miske, 2004, Use of the mechanical in-exsufflator in pediatric patients with neuromuscular disease and impaired cough, Chest, 125, 1406, 10.1378/chest.125.4.1406 Montes, 2010, Six-minute walk test demonstrates motor fatigue in spinal muscular atrophy, Neurology, 74, 833, 10.1212/WNL.0b013e3181d3e308 Munsat, 1992, International SMA consortium meeting. (26-28 June 1992, Bonn, Germany), Neuromuscul Disord, 2, 423, 10.1016/S0960-8966(06)80015-5 Najmabadi, 2011, Deep sequencing reveals 50 novel genes for recessive cognitive disorders, Nature, 478, 57, 10.1038/nature10423 Norman, 1961, Cerebellar hypoplasia in Werdnig-Hoffmann disease, Arch Dis Child, 36, 96, 10.1136/adc.36.185.96 Osawa, 1991, Werdnig-Hoffmann disease and variants, 15, 51 Oskoui, 2007, The changing natural history of spinal muscular atrophy type 1, Neurology, 69, 1931, 10.1212/01.wnl.0000290830.40544.b9 Pearn, 1978, A clinical and genetic study of spinal muscular atrophy of adult onset: the autosomal recessive form as a discrete disease entity, Brain, 101, 591, 10.1093/brain/101.4.591 Pera, 2017, 6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction, Neuromuscul Disord, 27, 879, 10.1016/j.nmd.2017.07.007 Poirier, 2018, Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs, Pharmacol Res Perspect, 6, 10.1002/prp2.447 Renbaum, 2009, Spinal muscular atrophy with pontocerebellar hypoplasia is caused by a mutation in the VRK1 gene, Am J Hum Genet, 85, 281, 10.1016/j.ajhg.2009.07.006 Roy, 1995, The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy, Cell, 80, 167, 10.1016/0092-8674(95)90461-1 Rudnik-Schöneborn, 1996, Clinical spectrum and diagnostic criteria of infantile spinal muscular atrophy: further delineation on the basis of SMN gene deletion findings, Neuropediatrics, 27, 8, 10.1055/s-2007-973741 Rudnik-Schöneborn, 2003, Extended phenotype of pontocerebellar hypoplasia with infantile spinal muscular atrophy, Am J Med Genet A, 117a, 10, 10.1002/ajmg.a.10863 Ruhno, 2019, Complete sequencing of the SMN2 gene in SMA patients detects SMN gene deletion junctions and variants in SMN2 that modify the SMA phenotype, Hum Genet, 138, 241, 10.1007/s00439-019-01983-0 Russman, 1996, Function changes in spinal muscular atrophy II and III, Neurology, 47, 973, 10.1212/WNL.47.4.973 Schreiber, 2016, Quantifying disease progression in amyotrophic lateral sclerosis using peripheral nerve sonography, Muscle Nerve, 54, 391, 10.1002/mus.25066 Shapiro, 1993, The diagnosis and orthopaedic treatment of childhood spinal muscular atrophy, peripheral neuropathy, Friedreich ataxia, and arthrogryposis, J Bone Joint Surg Am, 75, 1699, 10.2106/00004623-199311000-00017 Siegel, 1984, Upright mobility system for spinal muscular atrophy patients, Arch Phys Med Rehabil, 65, 418 Smeriglio, 2020, The identification of novel biomarkers is required to improve adult SMA patient stratification, diagnosis and treatment, J Pers Med, 10, 75, 10.3390/jpm10030075 Strauss, 2022, Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the phase III SPR1NT trial, Nat Med, 28, 1381, 10.1038/s41591-022-01866-4 Sumner, 2007, Molecular mechanisms of spinal muscular atrophy, J Child Neurol, 22, 979, 10.1177/0883073807305787 Swoboda, 2005, Natural history of denervation in SMA: relation to age, SMN2 copy number, and function, Ann Neurol, 57, 704, 10.1002/ana.20473 Takata, 2004, A new locus for recessive distal spinal muscular atrophy at Xq13.1-q21, J Med Genet, 41, 224, 10.1136/jmg.2003.013201 Thieme, 1993, Epidemiological data on Werdnig-Hoffmann disease in Germany (west-Thüringen), Hum Genet, 91, 295, 10.1007/BF00218278 Thompson, 1995, A novel cDNA detects homozygous microdeletions in greater than 50% of type I spinal muscular atrophy patients, Nat Genet, 9, 56, 10.1038/ng0195-56 Wadman, 2012, Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3, Neurology, 79, 2050, 10.1212/WNL.0b013e3182749eca Wallgren-Pettersson, 2004, 117th ENMC Workshop: ventilatory support in congenital neuromuscular disorders—congenital myopathies, congenital muscular dystrophies, congenital myotonic dystrophy and SMA (II) 4–6 April 2003, Naarden, The Netherlands, Neuromuscul Disord, 14, 56, 10.1016/j.nmd.2003.09.003 Wang, 2007, Consensus statement for standard of care in spinal muscular atrophy, J Child Neurol, 22, 1027, 10.1177/0883073807305788 Whelan, 1987, Neuropsychological performance of children with Duchenne muscular dystrophy and spinal muscle atrophy, Dev Med Child Neurol, 29, 212, 10.1111/j.1469-8749.1987.tb02138.x Wirth, 2006, Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number, Hum Genet, 119, 422, 10.1007/s00439-006-0156-7 Wu, 2017, A-44G transition in SMN2 intron 6 protects patients with spinal muscular atrophy, Hum Mol Genet, 26, 2768, 10.1093/hmg/ddx166 Yeo, 2020, Prospective cohort study of Nusinersen treatment in adults with spinal muscular atrophy, J Neuromuscul Dis, 7, 257, 10.3233/JND-190453 Zerres, 1999, 59th ENMC international workshop: spinal muscular atrophies: recent progress and revised diagnostic criteria 17-19 April 1998, Soestduinen, the Netherlands, Neuromuscul Disord, 9, 272, 10.1016/S0960-8966(99)00016-4 Zhao, 2016, Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy, Hum Mol Genet, 25, 1885, 10.1093/hmg/ddw062 Zou, 2007, SMN protects cells against mutant SOD1 toxicity by increasing chaperone activity, Biochem Biophys Res Commun, 364, 850, 10.1016/j.bbrc.2007.10.096